Source: Yicaixin
Author: Tang Ke
On June 6, the Shenzhen Stock Exchange updated and disclosed the listing application materials of Hangzhou Minsheng Health Pharmaceutical Co., Ltd. (hereinafter referred to as Minsheng Health). In this IPO, the sponsor hired by Minsheng Health is Caitong Securities , and the auditing agency is Zhonghui Club. It plans to raise 465 million yuan to be used for the intelligent production line technical transformation project of mineral OTC products, the intelligent production line technical transformation project of health food, and the technical transformation project of Minsheng Health R&D Center.
According to public information, Minsheng Health focuses on the research, development, production and sales of over-the-counter drugs and health foods for vitamins and minerals. It is the parent company behind "21 Jinweita®", one of the longest-standing brands in China with vitamins and mineral supplements. The sales of multi-dimensional element tablets (21) products have also become the main source of Minsheng Health's operating income. People's livelihood and health can conquer the world with a single product, but it will take some time to verify whether it can successfully enter the capital market.
pharmaceutical giant Sanofi once held
"Yicaixin" noticed that the predecessor of people's livelihood and health was once controlled by Sanofi-aventis (hereinafter referred to as Sanofi, France), one of the global pharmaceutical giants.
According to Guangzhou Daily, on January 29, 2010, France's Sanofi and Hangzhou Minsheng Pharmaceutical Co., Ltd. (hereinafter referred to as: Minsheng Pharmaceutical ), and the two parties jointly formed Hangzhou Sanofi Minsheng Health Pharmaceutical Co., Ltd. (the predecessor of Minsheng Health, hereinafter referred to as: Health Limited). At this point, France's Sanofi officially entered my country's over-the-counter drug market.
According to reports at the time, the joint venture is used to produce and operate over-the-counter drugs for vitamins and minerals, especially the "21 Jinweita" brand that was already in operation at the time will continue to "deeply cultivate" in the joint venture.
(screenshot from Guangzhou Daily)
Also According to Today's Morning Post, on November 3, 2010, Sanofi, France announced that Health Co., Ltd., a joint venture in the health pharmaceutical field established by it and Minsheng Pharmaceutical, recently received approval from the Ministry of Commerce. Sanofi in France accounts for 60.00% of the equity in the joint venture , and Minsheng Pharmaceutical accounts for 40.00% of the equity. As for the specific amount of the joint venture, no disclosure is made.
(screenshot from Guangzhou Daily)
At that time, France's Sanofi took a fancy to the brand strength of Minsheng Pharmaceutical's "21 Jinweita" and intended to use the joint venture to enter the Chinese over-the-counter drug market, but the final result was not satisfactory.
According to a report by Beijing Business Daily on January 17, 2017, Minsheng Pharmaceutical signed an equity transfer agreement with France Sanofi. Minsheng Pharmaceutical will acquire all 60.00% of the equity held by Sanofi. After the equity transfer and delivery is completed, the original joint venture will be wholly owned by Minsheng Pharmaceutical and fully responsible. The two parties ultimately failed to survive the "seven-year itch".
prospectus shows that Health Co., Ltd. was established on December 14, 2009. When the company was established, Minsheng Pharmaceutical held 100.00% of its equity; from October 2010 to March 2017, Health Co., Ltd. was an enterprise actually controlled by France Sanofi. Minsheng Pharmaceutical acquired the actual control of the company from France Sanofi in March 2017, and the cooperation between the two parties ended in a breakup.
Brand transfer was involved in bribery cases
When the aforementioned Minsheng Pharmaceutical cooperated with France Sanofi, it transferred the star brand "21 Jinweita" to its joint venture subsidiary Health Co., Ltd. for operation. A judicial document disclosed on the China Judgment Documents website mentioned the transfer of products related to Jinweita brand, Health Co., Ltd. was also involved in a bribery storm.
According to the second-instance criminal ruling in Tong's bribery case (released in August 2017), from 2009 to 2011, Tong, who was then the director of the Food Licensing Department and the Director of the Baohua Department of the State Food and Drug Administration, accepted the request of Zhang, chairman of Hangzhou Disheng Pharmaceutical Co., Ltd. (now known as Zhejiang Langxu Pharmaceutical Co., Ltd., hereinafter referred to as: Dison Pharmaceutical), and provided assistance to Hangzhou Minsheng Pharmaceutical Group Co., Ltd. (the enterprise controlled by the actual controller of Minsheng Health, hereinafter referred to as: Minsheng Group) to apply to the State Food and Drug Administration to transfer the Jinweita brand natural vitamin E capsule and other health foods under its name to health limited matters.To this end, Tong received or agreed to the relevant persons to accept money from Zhang from July 2011 to March 2015.
(screenshot from Judgment Documents Network)
Why did Dison Pharmaceutical Chairman Zhang play an important role as the briber in matters involving people's livelihood and health? What is the connection between Dison Medicine and people's livelihood and health?
Qichacha shows that Dison Pharmaceutical was established in March 1999. The current legal representative of , , actual controller, executive director and general manager is Zhang Zhulin, a natural person.
According to the company's industrial and commercial changes, on February 24, 2009, Zhang Zhulin, then the then Dison Pharmaceutical Manager, changed his position to executive director; on August 13, 2010, the executive director Zhang Zhulin was changed to supervisor, and the executive director and general manager was Liu Fei, the former manager of the company; on June 1, 2017, Zhang Zhulin, then the then supervisor, changed his position to executive director and general manager, and the position of company supervisor was Zhang Jieqing, the new shareholder in 2015.
It is worth noting that before Zhang Zhulin became the executive director in February 2009, the then executive director and shareholder of the company was Zhu Fuliang.
Search Qichacha, you can find that the natural person of the same name Zhu Fuliang was once the executive director and legal representative of Wenling Longsheng Metal Co., Ltd. (now cancelled, hereinafter referred to as: Longsheng Metal). Longsheng Metal was established in September 2008 and is owned by Hangzhou Minsheng Pharmaceutical Holding Group Co., Ltd. (hereinafter referred to as: Minsheng Holding ) and natural person Wan Zhigang each hold 50.00% of the shares.
(screenshot from Qichacha)
Qichacha shows that Minsheng Holdings currently has 22 natural person shareholders, and Minsheng Health’s actual controller Zhu Fujiang holds 53.3626% of its shares and serves as chairman.
It is unknown whether Zhu Fuliang, former executive director of Dison Pharmaceutical, has some relationship with Zhu Fujiang, the actual controller of Minsheng Health, and whether there are more interest disputes behind it. "Yicai Xin" will continue to pay attention to and bring related reports.
